Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AIM ImmunoTech Inc.
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
March 27, 2023
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
March 16, 2023
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
March 08, 2023
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Issues Letter to Stockholders
March 06, 2023
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
February 28, 2023
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
February 17, 2023
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
January 17, 2023
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
January 09, 2023
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
January 05, 2023
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
December 12, 2022
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
December 08, 2022
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
December 02, 2022
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 15, 2022
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
November 14, 2022
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Announces Corporate Governance Enhancements
November 09, 2022
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting
November 03, 2022
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease
November 02, 2022
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group’s Nominations Valid
October 31, 2022
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Board Issues Letter to Shareholders
October 26, 2022
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
October 12, 2022
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders
September 19, 2022
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
August 15, 2022
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
July 28, 2022
From
AIM ImmunoTech Inc.
Via
Globe NewsWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.